安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- TALZENNA Plus XTANDI Significantly Improves Radiographic . . . - Pfizer
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1 4 million new cases diagnosed globally in 2022 1 and 330,000 new cases anticipated in the United States in 2026 2 mCSPC, is a form of advanced prostate cancer that has spread beyond the prostate but is still sensitive to androgen inhibition 3 Despite recent
- Advanced and metastatic prostate cancer: ESMO Clinical Practice . . .
This ESMO Clinical Practice Guideline (CPG) focuses on advanced and metastatic prostate cancer This includes metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC)
- Niraparib and abiraterone acetate plus prednisone for HRR-deficient . . .
We hypothesized that PARP inhibition within 6 months of starting androgen deprivation therapy for metastatic castration-sensitive prostate cancer (mCSPC) could be effective and improve
- Phase 3 TALAPRO-3 trial meets primary end point in HRR-mutated mCSPC
The combination of talazoparib plus enzalutamide was previously approved in June 2023 for adult patients with HRR-mutatated metastatic castration-resistant prostate cancer The TALAPRO-3 trial is exploring the safety and efficacy of the combination earlier in the disease course
- Prostate Cancer, Version 3. 2026, NCCN Clinical Practice Guidelines In . . .
The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions for patients with prostate cancer across the disease spectrum The Guidelines sections included in this article focus on metastatic castration-sensitive prostate cancer (mCSPC), nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC) For patients with mCSPC, disease
- CUA Call-to-Action: Advanced Prostate Cancer (mCSPC) – 2026 Update . . .
Apply the latest guideline recommendations and evidence to optimize disease characterization and treatment selection in mCSPC Integrate advanced imaging, biomarker, and genetic testing into clinical decision-making to personalize therapy
- Top Prostate Cancer Trials to Watch at ASCO 2026 - OncoDaily
Talazoparib is a PARP inhibitor designed to exploit defects in DNA damage repair pathways, while enzalutamide is an androgen receptor pathway inhibitor widely used in advanced prostate cancer The study evaluates whether combining PARP inhibition with androgen receptor blockade can improve outcomes in biomarker-selected mCSPC
- FDA approves darolutamide for metastatic castration-sensitive prostate . . .
On June 3, 2025, the Food and Drug Administration (FDA) approved darolutamide (Nubeqa, Bayer Healthcare Pharmaceuticals Inc ) for metastatic castration-sensitive prostate cancer (mCSPC)
|
|
|